Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06206252 · ClinicalTrials.gov registry record
Can Medical Cannabis Affect Opioid Use?
A clinical trial of Pain and Chronic Pain, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- 110
- Enrollment target
- 1
- Study location
NCT06206252: Recruiting study of Pain and Chronic Pain, sponsored by Thomas Jefferson University.
NCT06206252 is a study of Pain and Chronic Pain that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 110 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06206252, a study of Pain and Chronic Pain, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn how medical cannabis (MC) affects pain and the use of opioid pain medications. Participants who have chronic pain and use prescribed opioid pain medication will opt-in to using MC or not for the 3-month study. Participants who are certified in Pennsylvania will purchase specific medical cannabis products at a reduced cost from a partnering medical cannabis dispensary monthly. All participants will complete baseline, daily, and monthly assessments to observe changes across groups.
Primary Outcome
Measured using Brief Pain Inventory Short Form (BPI-SF), scores 0-10 with higher scores indicating more pain severity
Conditions Studied
Interventions
- OTHER Medical Cannabis
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-09-07 |
| Est. Completion | 2026-01 |
What NCT06206252 shows while recruiting
NCT06206252 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Medical Cannabis is the first listed.
NCT06206252 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06206252 about?
NCT06206252 is a clinical study titled "Can Medical Cannabis Affect Opioid Use?". The goal of this observational study is to learn how medical cannabis (MC) affects pain and the use of opioid pain medications. Participants who have chronic pain and use prescribed opioid pain medication will opt-in to using MC or not for the 3-month study. Participants who are certified in Pennsyl...
What is the current status of trial NCT06206252?
This trial is currently recruiting. The enrollment target is 110 participants. The study started on 2023-09-07. Estimated completion is 2026-01.
What conditions does trial NCT06206252 study?
This clinical trial studies the following conditions: Pain, Chronic Pain.
What interventions are being tested in trial NCT06206252?
The interventions under investigation include: Medical Cannabis (OTHER).
Who is sponsoring clinical trial NCT06206252?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06206252 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06206252's enrollment target sits among peer trials
110 154th of 374 higher than 221 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Postoperative Pain After Activation of Irrigant
RECRUITING · NA
-
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)
RECRUITING · NA
-
Reliability of Pupil Response to Acute Pain
RECRUITING
-
Pain With Dementia
RECRUITING · NA
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Defense and Veterans Center for Integrative Pain Management (DVCIPM) Pain Registry Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI